Literature DB >> 3297620

Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.

S P Clissold, S Lynch, E M Sorkin.   

Abstract

Buflomedil hydrochloride is a vasoactive drug with a variety of pharmacodynamic properties. Importantly, it seems to improve nutritional blood flow in ischaemic tissue of patients with peripheral and/or cerebral vascular disease by a combination of pharmacological effects: inhibition of alpha-adrenoceptors, inhibition of platelet aggregation, improved erythrocyte deformability, nonspecific and weak calcium antagonistic effects, and oxygen sparing activity. Therapeutic trials with buflomedil in patients with peripheral vascular diseases have shown that it increases walking distances in those with intermittent claudication and heals trophic lesions and reduces rest pain in many patients with more severe vasculopathies. In open clinical trials a good to very good clinical response was achieved in 57 to 87% of those treated. In comparative studies buflomedil 600 mg/day orally was shown to be significantly superior to placebo and comparable in efficacy to pentoxifylline (oxpentifylline) and naftidrofuryl. In patients with symptoms presumed to be due to cerebrovascular insufficiencies and elderly patients with senile dementia, buflomedil 450 to 600 mg/day alleviated symptoms associated with impairment of cognitive and psychometric function and was significantly superior to placebo and slightly more effective than drugs such as cinnarizine, flunarizine and co-dergocrine mesylate. Overall, buflomedil at dosages of up to 600 mg/day has been very well tolerated and discontinuation of therapy has rarely been necessary. Thus, buflomedil would seem to be a useful adjunct to conservative treatment in patients with mild-to-moderate peripheral vascular disease and/or cerebrovascular insufficiency, and well worth a try in patients with more severe peripheral disease unable to undergo surgery. However, a few well-designed long term studies are needed to fully define its overall place in therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297620     DOI: 10.2165/00003495-198733050-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  60 in total

1.  Editorial: The prevalence and malignancy of Alzheimer disease. A major killer.

Authors:  R Katzman
Journal:  Arch Neurol       Date:  1976-04

2.  Controlled evaluation of drugs in chronic vascular disease.

Authors:  G Trübestein
Journal:  Angiology       Date:  1981-10       Impact factor: 3.619

3.  Effects of buflomedil in a group of patients with chronic peripheral arterial diseases. Clinical and hemorheological evaluation.

Authors:  E Mozzi; D Chiurazzi; A Spinola; F Annoni; R Germiniani
Journal:  J Int Med Res       Date:  1985       Impact factor: 1.671

4.  Double blind comparative study of cinnarizine and buflomedil in patients suffering from cerebrovascular insufficiency.

Authors:  A Pacheco e Silva; A M Landi de Almedia
Journal:  Angiology       Date:  1981-10       Impact factor: 3.619

5.  [Acute poisoning by buflomedil].

Authors:  C Medernach; R Garnier; M L Efthymiou
Journal:  Nouv Presse Med       Date:  1981-11-21

6.  [Epidemiologic study of peripheral obstructive arteriopathies: clinical effects of treatment with buflomedil chlorhydrate (Loftyl). Processing of data furnished by a polycenter study].

Authors: 
Journal:  Minerva Med       Date:  1985-10-13       Impact factor: 4.806

7.  The effect of buflomedil in diabetic retinopathy estimated by ocular fluorophotometry.

Authors:  J J Kjaergaard; J Ditzel
Journal:  Int J Microcirc Clin Exp       Date:  1987-08

8.  Effects of buflomedil on the responsiveness of canine vascular smooth muscle.

Authors:  P M Vanhoutte; L L Aarhus; E Coen; R R Lorenz; T J Rimele; T J Verbeuren
Journal:  J Pharmacol Exp Ther       Date:  1983-12       Impact factor: 4.030

9.  Effects of buflomedil on isolated dog arteries.

Authors:  N Toda; H Okunishi; T Okamura; M Miyazaki
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-11

Review 10.  An experimental overview of a new vasoactive drug: buflomedil HCl.

Authors:  A Dubourg; R F Scamuffa
Journal:  Angiology       Date:  1981-10       Impact factor: 3.619

View more
  8 in total

Review 1.  Drugs that alter blood viscosity. Their role in therapy.

Authors:  A M Ehrly
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

2.  Effects of torbafylline, pentoxifylline and buflomedil on vascularisation and fibre type of rat skeletal muscles subjected to limited blood supply.

Authors:  O Hudlická; S Price
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

3.  [Adenosine for treatment of ischemic pain in thromboangiitis obliterans. A case report].

Authors:  Philip M Lang; D Irnich
Journal:  Schmerz       Date:  2007-06       Impact factor: 1.107

4.  Separation of pyrrolidine from tetrahydrofuran by using pillar[6]arene-based nonporous adaptive crystals.

Authors:  Jiajun Cao; Yitao Wu; Qi Li; Weijie Zhu; Zeju Wang; Yang Liu; Kecheng Jie; Huangtianzhi Zhu; Feihe Huang
Journal:  Chem Sci       Date:  2022-06-02       Impact factor: 9.969

5.  Buflomedil poisoning: five cases with cardiotoxicity.

Authors:  A Legras; R Piquemal; Y Furet; P F Dequin; D Perrotin
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

Review 6.  Acute buflomedil intoxication: a life-threatening condition.

Authors:  A Alberti; S Valenti; F Gallo; M Petolillo; D Del Monte
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

Review 7.  Buflomedil for acute ischaemic stroke.

Authors:  Simiao Wu; Quantao Zeng; Ming Liu; Jie Yang; Sha He; Sen Lin; Bo Wu
Journal:  Cochrane Database Syst Rev       Date:  2015-07-20

8.  Effects of buflomedil and pentoxifylline on hamster skin-flap microcirculation: prediction of flap viability using orthogonal polarization spectral imaging.

Authors:  Denise Salles Coelho da Mota; Eliane Furtado; Daniel Alexandre Bottino; Eliete Bouskela
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.